Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group

Analysis of 2 studies (n=8196) found discontinuation of asparaginase doses linked to inferior disease-free survival in higher-risk patients (HR 1.5; 95% CI, 1.2-1.9; p= 0.002) vs. those receiving all prescribed doses, illustrating severe consequences of shortages of the drug.


Journal of Clinical Oncology